30 closest matches · ranked by relevance
Carcinoma of the Appendix · Primary Peritoneal Cavity Cancer
Primary: The Difference in the Number of Grade 3 or 4 Hematologic Toxicities (Leukopenia, Thrombocytopenia, and Neutropenia) Between the Mitomycin C and Oxaliplatin Treatments…
Gynecologic Cancer · Gynecologic Neoplasms · Peritoneal Carcinomatosis
Primary: Proportion of Participants Who Are Successfully Down Staged to Resectable Based on Peritoneal Carcinomatosis Index (PCI) and Principal Investigator (PI) Discretion…
Gastrointestinal Cancer
Primary: Number of Participants With Overall Response — 3; 12 participants
Colorectal Cancer · Cancer of Gastrointestinal Tract
Primary: Response Rate in CIMP-High Colorectal Cancer and Small Bowel Adenocarcinoma (SBA) — 0; 0; 0; 2 Participants
Gastrointestinal Neoplasm
Primary: Progression Free Survival
Anal Cancer · Rectal Cancer
Primary: Percentage of Participants With Best Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 — 2.8 percentage of participants
Peritoneal Carcinomatosis · Colorectal Cancer · Appendiceal Cancer
Primary: Completeness of Cytoreduction
Colorectal Neoplasms · Peritoneal Neoplasms
Primary: Peritoneal Recurrence Free Survival at 18 Months — 79; 80 participants
Carcinoma of the Appendix · Colorectal Cancer
Primary: Time to Progression — 0.775 years
Stage II Gallbladder Cancer · Stage IIIA Gallbladder Cancer · Stage IIIB Gallbladder Cancer
Primary: Response Rate According to RECIST Criteria — 3; 0 participants
Pancreatic Cancer Non-resectable · Pancreatic Cancer Metastatic
Primary: Disease Control Rate (DCR) at 4 Months Using RECIST 1.1 — 2 Participants
Appendicitis · Perforated Appendicitis · Ruptured Appendicitis
Primary: Overall Cost of Care
Epidermoid Carcinoma · Anus
Primary: Percentage of Patients With Complete Response to Treatment — 30; 10; 0; 4 Participants
Gastrointestinal Cancer
Primary: Response Rate (RR) — 19 Participants
Cancer of the Gallbladder · Cancer of the Biliary Tract
Primary: Number of Participants With Objective Response — 1 participants
Extrahepatic Bile Duct Cancer · Gallbladder Cancer
Primary: Stratum-specific (R0 and R1) 2-year Overall Survival — 67; 60 percentage of participants
Operation Finding · Complications · Pathology
Primary: Histopathological Outcomes Obtained Through the Surgeries — 20.3; 19.2 nodes
Metastatic Pancreatic Cancer
Primary: Survival for Patients With Metastatic Pancreatic Cancer With First-line Treatment With FOLFOX-A as Compared to Historical Controls of Gemcitabine Alone. — 5; 11 months
Peritoneal Carcinomatosis
Primary: Percentage of Patients That Had at Least One Additional Lesion Detected Under Pegsitacianine Guidance Following CRS That Was Confirmed as Positive for Disease by…
Neoplasms, Unknown Primary
Primary: Progression Free Survival — 3.7 months
Pancreatic Cancer
Primary: Progression-free Survival at 6 Months — 82 percentage of participants
Complicated Appendicitis · Acute Appendicitis
Primary: Feasibility of the Use of Antibiotic Solution Instillation Following Intraoperative Diagnosis of Complex Appendicitis as Assessed by Percentage of Eligible Participants…
Ampulla of Vater Adenocarcinoma · Small Intestinal Adenocarcinoma · Stage III Ampulla of Vater Cancer AJCC v8
Primary: Number of Participants With Progression-free Survival (PFS) at Six Months — 68 percentage of participants
Appendicitis
Primary: Negative Appendectomy — 6; 6; 166; 180 participants
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Adenomatous Polyps
Primary: Percent of Incompletely Resected Adenomatous Polyps — 10.1 percentage of incomplete resection
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants
Pancreatic Cancer
Primary: Response Rate — .125 proportion of participants
Adult Primary Cholangiocellular Carcinoma · Advanced Adult Primary Liver Cancer · Cholangiocarcinoma of the Extrahepatic Bile Duct
Primary: Overall Survival — 4.7; 1.6; 3.94 months